Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8001 vs Lapatinib + Capecitabine in HER2+ Advanced Breast Cancer
NCT04185649Phase 3Unknown
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jul 2018
- Primary completion
- Jul 2020
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of BAT8001 in HER2-positive breast cancer, sponsored by Bio-Thera Solutions, Ltd.. Status: unknown.
02
Drugs
BAT8001
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04185649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04185649.